Last updated on February 2018

Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

Brief description of study

This is a registry study in adult patients with newly diagnosed or refractory/relapsed acute myeloid leukemia.

Investigator's sites: 40 sites in Germany.

Primary objectives:

  • Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry.
  • Evaluation of the most important patient-relevant clinical endpoints (outcomes): relapse-free survival (RFS) / time to relapse (TTR), calculation of cumulative incidence of relapse (CIR) and overall survival (OS)
  • Documentation of treatment strategy

Detailed Study Description

see brief summary

Clinical Study Identifier: NCT03188874

Contact Investigators or Research Sites near you

Start Over

Krankenhaus D ren gGmbH

Düren, Germany
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.